0000950123-10-109837.txt : 20110314 0000950123-10-109837.hdr.sgml : 20110314 20101130190916 ACCESSION NUMBER: 0000950123-10-109837 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20101130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 BUSINESS PHONE: 2054444600 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 CORRESP 1 filename1.htm corresp
     
 
  Robyn Zolman
November 30, 2010
  Direct: 303.298.5740
 
  Fax: 303.313.2830
 
  RZolman@gibsondunn.com
 
  Client: C 12412-00001
VIA EDGAR
Ms. Rose Zukin
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:   BioCryst Pharmaceuticals, Inc.
Form 10-K for the year ended December 31, 2009
Filed March 9, 2010
Definitive Proxy Statement on Schedule 14A
Filed April 6, 2010
File No. 000-23186
Dear Ms. Zukin:
On behalf of BioCryst Pharmaceuticals, Inc. (the “Company”) this letter confirms that as discussed with you today, the Company will respond to the Staff’s November 16, 2010 letter to the Company on or before December 15, 2010.
Sincerely,
/s/ Robyn Zolman
Robyn Zolman
REZ/rez
cc:   Alane Barnes, BioCryst Pharmaceuticals, Inc.
Brian Lane, Gibson, Dunn & Crutcher LLP